Clinical Trial

SKB410 for Injection in Solid Tumors

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-05
notable Enrollment reduced: 54 -> 38 participants 2026-08-05
notable Primary completion moved earlier: 2026-12-30 -> 2026-03-31 2026-08-05
minor Completion moved earlier: 2026-12-30 -> 2026-03-31 2026-08-05
Trial Details
NCT Number NCT05906537
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 38 participants
Start Date 2023-07-06
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-04